Exelixis Q2 2024 Adj. EPS $0.84 Beats $0.30 Estimate, Sales $637.178M Beat $465.005M Estimate
Portfolio Pulse from Benzinga Newsdesk
Exelixis (NASDAQ:EXEL) reported Q2 2024 adjusted EPS of $0.84, significantly beating the estimate of $0.30. The company also reported sales of $637.178 million, surpassing the estimate of $465.005 million and marking a 35.61% increase from the same period last year.
August 06, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exelixis reported Q2 2024 adjusted EPS of $0.84, beating the estimate of $0.30 by 180%. Sales of $637.178 million also exceeded the estimate of $465.005 million, marking a 35.61% increase from the same period last year.
Exelixis' strong earnings and revenue performance, significantly beating analyst estimates, is likely to positively impact its stock price in the short term. The substantial year-over-year sales growth further supports a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100